Such stuff as dreams are made on: mediator-directed therapy in sepsis.

作者: John C. Marshall

DOI: 10.1038/NRD1084

关键词: Intensive care unitClinical realityCause of deathClinical trialMicrobial toxinsSepsisClinical syndromeMediatorIntensive care medicineMedicine

摘要: Sepsis, a life-threatening disorder that arises through the body's response to infection, is leading cause of death and disability for patients in an intensive care unit. Advances understanding complex biological processes responsible clinical syndrome have led identification many promising new therapeutic targets, including bacterial toxins, host-derived mediators, downstream such as coagulation endocrine response. Diverse therapies directed against these targets shown dramatic effects animal models; however, humans, their impact has been frustratingly modest, only one agent--recombinant activated protein C--has achieved regulatory approval. This review summarizes approaches evaluated trials, explores reasons discordance between promise reality, points may lead greater success future.

参考文章(161)
Marissa M Alejandria, Mary Ann D Lansang, Leonila F Dans, Jacinto Blas Mantaring III, Intravenous immunoglobulin for treating sepsis and septic shock. Cochrane Database of Systematic Reviews. ,(2000) , 10.1002/14651858.CD001090
Dinarello Ca, Revhaug A, Michie Hr, Manogue Kr, Sherman Ml, Wolff Sm, O'Dwyer St, Cerami A, Arthur K, Spriggs Dr, Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery. ,vol. 104, pp. 280- 286 ,(1988)
CHARLES J. FISHER, STEVEN M. OPAL, JEAN-FRANÇOIS DHAINAUT, SUE STEPHENS, JANICE L. ZIMMERMAN, PETER NIGHTINGALE, SIMON J. HARRIS, ROLAND M. H. SCHEIN, EDWARD A. PANACEK, JEAN-LOUIS VINCENT, GARRETT E. FOULKE, EDWARD L. WARREN, CHRIS GARRARD, GILBERT PARK, MARK W. BODMER, JONATHAN COHEN, CEES VAN DER LINDEN, ALAN S. CROSS, JERALD C. SADOFF, Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis Critical Care Medicine. ,vol. 21, pp. 318- 327 ,(1993) , 10.1097/00003246-199303000-00006
Lisa G. Criscione, E. William St. Clair, Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases Current Opinion in Rheumatology. ,vol. 14, pp. 204- 211 ,(2002) , 10.1097/00002281-200205000-00002
H C Polk, M J Hershman, S R Wellhausen, G Sonnenfeld, S H Appel, Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clinical and Experimental Immunology. ,vol. 77, pp. 67- 70 ,(1989)
John C. Marshall, Rethinking Sepsis: From Concepts to Syndromes to Diseases Sepsis. ,vol. 3, pp. 5- 10 ,(1999) , 10.1023/A:1009830809222
Jean-Francois A. Dhainaut, Jean-Louis Vincent, Christian Richard, Philippe Lejeune, Claude Martin, Lisiane Fierobe, Sue Stephens, Ursula M. Ney, Mark Sopwith, CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Critical Care Medicine. ,vol. 23, pp. 1461- 1469 ,(1995) , 10.1097/00003246-199509000-00004